Exploration on the epidemiological characteristics and therapeutic measures of 62 patients with diffuse large B-cell lymphoma in our hospital

Abstract

Objective To explore the epidemiological characteristics and therapeutic measures of 62 patients with diffuse large B-cell lymphoma (DLBCL) in our hospital. Methods From December 2011 to December 2018, 62 DLBCL patients in our hospital were selected. Age, sex, initial symptoms, extranodal organ involvement, physical condition score (ECOG), combined radiotherapy, international prognostic index of lymphoma (IPI), B symptom, first-line median chemotherapy cycle, Ann Arbor stage of lymphoma, surgery, serum lactate dehydrogenase (LDH), bone marrow invasion, Hans pathological type were collected. CHOP-based chemotherapy regimen was given to DLBCL patients. Epidemiological characteristics of 62 DLBCL patients were analyzed, and remission rates of chemotherapy + rituximab and chemotherapy alone were compared. Results The proportion of DLBCL patients less than 60 years old was higher than that of DLBCL patients equal or more than 60 years old, and the proportion of male patients was higher than that of female patients. The initial symptoms were lymph nodes, pharynx symptoms, and gastrointestinal symptoms. The main involved extranodal organs were Wechsler's ring, gastrointestinal tract, bone marrow, and spleen. The proportion of patients with ECOG score of 0-1 was higher than that of patients with ECOG score of 2, the proportion of patients with IPI index of 0 or 1, 2, 3, 4 or 5 decreased in turn. Phase II of the Ann Arbor stage of lymphoma accounted for the highest proportion, phase I for the lowest. The proportion of patients with abnormal serum LDH level was higher than that of patients with normal serum LDH level. The proportion of non-germinal center source of Hans pathological type was higher than that of germinal center source. The remission rate of chemotherapy + rituximab was 84.38%, higher than that of chemotherapy alone (60.00%) (P<0.05). Conclusions DLBCL is predominant in middle-aged people under 60 years old, especially in men. The initial symptoms are lymph node, pharynx and gastrointestinal tract symptoms. The main extranodal organs involved are Wechsler's ring, gastrointestinal tract, bone marrow, and spleen. Abnormal serum LDH and non-germinal center sources are more common. The stage of the disease is mainly over stage II. CHOP chemotherapy combined with rituximab is used to treat DLBCL, which can improve the remission rate and make a reference for early diagnosis and treatment of DLBCL. Key words: Therapeutic measure; Diffuse large B-cell lymphoma; Epidemiological characteristics